Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096929 | 0.78 | CA12 (0.33) | PTPRCCA12CA2CA14 | |
| SCHEMBL6759385 | 0.74 | CA12 (0.34) | PTPRCCA12CA2CA14 | |
| SCHEMBL6099336 | 0.74 | CA12 (0.34) | PTPRCCA12CA2CA14 | |
| SCHEMBL756932 | 0.70 | CA2 (0.39) | PTPRCCA12CA2CA14 | |
| SCHEMBL2586166 | 0.67 | MEN1 (0.35) | PTPRCCA12CA2CA14 | |
| SCHEMBL10209059 | 0.67 | CA2 (0.39) | PTPRCCA12CA2CA14 | |
| SCHEMBL6937980 | 0.67 | MEN1 (0.40) | PTPRCCA12CA2CA14 | |
| SCHEMBL21564883 | 0.66 | CA2 (0.36) | PTPRCCA12CA2CA14 | |
| SCHEMBL23894059 | 0.66 | CA2 (0.41) | PTPRCCA12CA2CA14 | |
| SCHEMBL783009 | 0.66 | CA2 (0.41) | PTPRCCA12CA2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109352-B2 | Process for producing optically active amino acid derivatives | KANEKA CORPORATION (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20050143586-A1 | Process for producing optically active amino acid derivatives | KANEKA CORPORATION (JP) | 2005-06-30 | — | — | US | disclosed |
| US-6720449-B2 | N-PROTECTING AN OPTICALLY ACTIVE 3-HALOALANINE DERIVATIVE FOLLOWED BY CYCLIZATION FOR AZIRIDINE-2-CARBOXYLIC ACID DERIVATIVES | KANEKA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20030032814-A1 | Process for preparing optically active amino acid derivatives | KANEKA CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1179530-A1 | PROCESSES FOR PREPARING OPTICALLY ACTIVE AMINO ACID DERIVATIVES | Kaneka Corporation (JP) | 2002-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143586-A1 | Process for producing optically active amino acid derivatives | NPEPPS, AAAS, DDC | PTPRC 3904/4885CA12 1984/4885CA2 286/4885 |
| US-20030032814-A1 | Process for preparing optically active amino acid derivatives | NPEPPS, AAAS, DDC | PTPRC 3907/4885CA12 2363/4885CA2 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.